Journal Articles Euroasian Journal of Hepato-Gastroenterology Year : 2024

HeberNasvac: Development and Application in the Context of Chronic Hepatitis B

Marie-Louise Michel
  • Function : Author
  • PersonId : 839381

Abstract

The immune system plays a central role in controlling acute hepatitis B infection and in patients resolving chronic hepatitis B (CHB). Given that 221 million (75%) of CHB patients reside in low-and middle-income countries, the development of a vaccine with therapeutic properties represents a rational and cost-effective approach more than a romantic endeavor. This review systematically analyzes the key variables related to the safety, efficacy, and effectiveness of CHB treatments. HeberNasvac experience is revisited for addressing the challenges and potentialities of therapeutic vaccines, as well as the current roadblocks in research and development, registration, and large-scale implementation.
Fichier principal
Vignette du fichier
2024 HeberNasvac euroasian journal hepato-gastro.pdf (1.07 Mo) Télécharger le fichier
Origin Files produced by the author(s)
Licence

Dates and versions

hal-04926485 , version 1 (03-02-2025)

Licence

Identifiers

Cite

Julio C Aguilar, Sheikh Mf Akbar, Mamun Al-Mahtab, Md Sakirul I Khan, Carlos A Guzman, et al.. HeberNasvac: Development and Application in the Context of Chronic Hepatitis B. Euroasian Journal of Hepato-Gastroenterology, 2024, 14 (2), pp.221-237. ⟨10.5005/jp-journals-10018-1457⟩. ⟨hal-04926485⟩
0 View
0 Download

Altmetric

Share

More